TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Complexa raises $13M to fund trials of kidney disease drug

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Wednesday, June 4, 2014, 10:51 a.m.
 

Complexa Inc., a South Side-based drug development company, said it raised $13 million from investors that will fund clinical trials of a drug to treat kidney disease.

The funding round, Complexa's second, was led by Jafco Life Science Investment, an arm of Japanese private equity firm Jafco Co. Ltd.

The company previously raised more than $8 million from venture capital investors to license and develop molecules discovered and patented by professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

There is “great interest” in Complexa's work from large pharmaceutical companies, Jafco officials said in a statement.

Add Alex Nixon to your Google+ circles.

 

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Large-scale batteries are integral in shift to renewable energy
  2. Plastics, tech sectors crucial to cracker plants
  3. Energy Spotlight: Steve Anthos
  4. Student loan debt presents paradox
  5. Without pipelines, gas can’t get to demand
  6. Open enrollment puts varied impact of health care law back in focus
  7. EDMC loses $664M; executives receive six-figure bonuses
  8. Mortgage in reach despite few dings
  9. Hackers rip into heart of open-source software
  10. Universal theme park swings into Beijing
  11. Value, convenience are top priorities of Highmark, new CEO Holmberg says
Subscribe today! Click here for our subscription offers.